Sorry!! The article you are trying to read is not available now.
All Biotech/pharma Articles

By Brett Chase Oct 31, 2012 11:40 am

FDA panels and a first look at data from a blood disease conference should move stocks during the month. An approval decision on Exelixis' cancer drug is expected by the end of the month.   Read this article